4-Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias. A pilot study

A. M. Carella, G. Santini, M. Martinengo, D. Giordano, S. Nati, A. Congiu, R. Cerri, M. Risso, E. Damasio, E. Rossi

Research output: Contribution to journalArticlepeer-review


Twenty-five adults with previously treated acute leukemia were treated with 4-demethoxydaunorubicin (Idarubicin) with a daily dose of 8 mg/m2 for 3 days intravenously. Complete remission was achieved in 3 of 18 patients with acute nonlymphatic leukemia (ANLL) and 2 of 6 with lymphoblastic leukemia. Complete remissions were observed in two of eight ANLL patients refractory to cytarabine, anthracycline, and m-Amsa (amsacrine), indicating a lack of cross-resistance between these drugs and Idarubicin. The median duration of remission was 8 weeks. The main major toxicity of Idarubicin therapy, severe myelosuppression, cannot be considered a toxic effect because it was desired in this case list. Our preliminary results indicate that Idarubicin has significant activity against refractory adult acute leukemia.

Original languageEnglish
Pages (from-to)1452-1454
Number of pages3
Issue number7
Publication statusPublished - 1985

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of '4-Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias. A pilot study'. Together they form a unique fingerprint.

Cite this